EGFR and neoplasm: The overall estimated HR for PFS was 2.00 (95% CI: 1.73–2.31, p < .001, Figure 2A), which indicated that EGFR+ in both tumor tissue and plasma at baseline is the worse prognostic factor for NSCLC treated with EGFR TKIs.